Alicaforsen: Isis Pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 2, Issue 10, 2001, Pages 1401-1406

  Gewirtz, A T ^a   Sitaraman, S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; INTERCELLULAR ADHESION MOLECULE 1; ISIS 1570; ISIS 15839; ISIS 2302 CS2; ISIS 2302 CS3; ISIS 2302 CS9; PLACEBO; UNCLASSIFIED DRUG;

ASTHMA; CELL ADHESION; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NAUSEA; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; ARTHRITIS, RHEUMATOID; ASTHMA; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PSORIASIS; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES;

EID: 0034771823     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides
2. BI/Isis to collaborate in cell adhesion
3. Oligonucleotide conjugates aimed to improve the pharmacokinetic properties of antisense agents
4. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters
5. Isis initiates phase II clinical trials of ISIS 2302, an antisense compound to treat inflammatory diseases
6. Pharmacokinetics of ISIS-2302, a phosphorothioate (P=S) oligonucleotide, in cynomolgus monkeys after intravenous infusion and bolus injection
7. Effects of ISIS-2302, a phosphorothioate olignucleotide, on in vitro and in vivo coagulation parameters
8. ISIS demonstrates attractive pharmacokinetics of second and third generation antisense compounds in animals
9. Patent news update
10. Phase 1 study of an ICAM-2 antisense oligonucleotide (ISIS 2302)
11. In vitro and in vivo effects of cholesterol conjugated ICAM-1 antisense oligonucleotides
12. Oligonucleotide conjugates: Alteration of the pharmacokinetic properties of antisense agents
13. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
14. Boehringer Ingelheim and Isis reach first milestone for ISIS-2302
15. Isis receives $10 million milestone payment from Boehringer Ingelheim for ISIS-2302
16. Isis receives second payment from Boehringer Ingelheim on line of credit to support cell adhesion collaboration
17. Isis receives thirteen patents covering antisense biology, chemistry and combinatorial chemistry novel biology targets include Ras, cell adhesion, CMV, HIV and flu
18. Single dose subcutaneous bioavailability of ISIS 2302, a phosphorothioate olignucleotide, in cynomolgus monkeys
19. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys
20. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)
21. Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucloetide in a 4-week study in CD-1 mice
22. Inhibition of coagulation by a phosphorothioate oligonucleotide
23. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues
24. Efforts toward synthesis of oligonucleotides for commercialization
25. Pharmacokinetic properties of phosphorothioate oligonucleotides
26. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
27. Isis Pharmaceuticals reports second quarter 1998 results
28. Isis reports year end and fourth quarter results for 1998
29. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
30. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1
31. Safety of retreatment with antisense to ICAM-1 (ISIS 2302) in patients with steroid-dependent Crohn's disease
32. Isis reacquires full rights to ISIS-2302; Isis plans DNA filing in early 2000 pending review of data
33. Isis in late stage negotiations to commercialize ISIS-2302
34. Isis presents data from phase II trial of ISIS 2302 in rheumatoid arthritis
35. Isis begins phase IIa study of ISIS 2302 for ulcerative colitis
36. Isis announces disappointing results from ISIS-2302 clinical trial in Crohn's disease
37. Isis Pharmaceuticals Inc annouces restructing and exposure reduction plan; company has approximately 3 years of cash under the new operating plan
38. CytoGenix sponsors study at Baylor using Isis antisense molecule
39. Isis Pharmaceuticals reports significantly reduced expenses for the second quarter 2000, balance sheet reflects strong cash position
40. Isis Pharmaceuticals to reinitiate development of ISIS 2302 in Crohn's disease final analysis of clinical trial shows response to drug in patients with higher levels of exposure
41. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys
42. A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroid dependent Crohn's disease showed clinical improvement at high serum levels
43. Digestive Disease Week 2001 - Overnight Report, Atlanta, GA, USA
44. Exposure to higher levels of ISIS 2302 improves potential for complete, durable remissions and reduction to steroids in patients with Crohn's disease